News and Trends 9 Dec 2022
Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients
Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene…